The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on 2025-05-22. This approval, classified for efficacy, expands the therapeutic scope of the drug.
Background
Keytruda (pembrolizumab) is sponsored by MERCK SHARP DOHME. This supplemental approval specifically pertains to the drug's efficacy profile.
What this means
This supplemental approval indicates that the FDA has recognized additional evidence supporting the efficacy of Keytruda (pembrolizumab). While specific details of the expanded indication or patient population are not provided, such approvals typically broaden the conditions or groups for which the drug can be prescribed.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA) on 2025-05-22. Details are available on accessdata.fda.gov, under supplemental application BLA125514 S-182.